Anthropic 收购一人生物科技初创公司 Mithril Medicine，正式开展自有药物研发。其创始人借助 Claude 与 11 家外部实验室，在不到 18 个月内将一款罕见肌肉萎缩症潜在疗法从构想推进到小鼠实验的积极结果。推文认为药物研发将成为重要收入来源，此举也意在 IPO 前向投资者释放业务持续增长的信号。
A few thoughts on Anthropic’s approach:
1. Drug discovery will be one of the most significant revenue streams in the future; the goal here is to set the right course early on. Most diseases will become treatable, a market encompassing 7 billion people.
2. The timing is clearly intentional, announced just before the IPO to signal to investors that the business will continue to thrive in the future.
3. This will likely make it clear, even to those outside the "tech nerd" sphere, why AI is so important. It goes beyond just writing code; it solves problems for humanity.
Anthropic is now doing its own drug discovery after acquiring one-person biotech startup Mithril Medicine! With Claude and 11 external labs, its founder took a potential treatment for a rare form of muscular dystrophy from idea to promising results in mice in under 18 months.在 X 查看被引用的帖子
来源：Chubby♨️ · x.com